Inclusion Criteria

          -  Unless otherwise noted, subjects must meet all of the following criteria to
             participate in this study:

          -  Written informed consent and HIPAA authorization for release of personal health
             information. Subjects or their Legally Authorized Representative must sign a consent
             to undergo cell procurement. Written informed consent to enroll in the CAR T-cell
             therapy trial must be obtained prior to lymphodepletion.

          -  Adults ≥18 years of age.

          -  Subjects must have one of the following diagnoses by WHO criteria:

               -  Classic Hodgkin Lymphoma

               -  Mycosis fungoides

               -  Sezary syndrome

               -  Primary cutaneous CD30 positive T cell lymphoproliferative disorder including
                  lymphomatoid papulosis or primary cutaneous anaplastic large cell lymphoma

               -  B-cell lymphoma, unclassifiable, with features intermediate between DLBCL and
                  classic Hodgkin Lymphoma (Grey Zone Lymphoma)

          -  Diagnosis of recurrent lymphoma in subjects who have failed ≥2 prior treatment
             regimens.

          -  These prior treatment regimens must include brentuximab vedotin.

          -  If the subject has Hodgkin Lymphoma, the subject must have either failed autologous
             transplant or must not be eligible for autologous transplant.

          -  If the subject has grey zone lymphoma, the subject must have failed an anthracycline
             containing regimen unless the subject was not previously a candidate for anthracycline

          -  Subjects relapsed after autologous or allogeneic stem cell transplant are eligible for
             this study.

          -  CD30+ disease (result can be pending at the time of cell procurement, but must be
             confirmed prior to treatment with ATLCAR.CD30.CCR4 and ATLCAR.CD30 cells); NOTE: CD30+
             disease requires documented CD30 expression by immunohistochemistry based on the
             institutional hematopathology standard.

          -  Karnofsky score of > 60%

          -  For Subjects in the Expansion Cohort: Willing to undergo biopsy following the cell
             infusion. A biopsy may be required (i.e., considered mandatory) in subjects receiving
             both cellular products if the Investigator determines the tumor site is easily
             accessible (e.g., palpable tumor). If the Investigator feels that the biopsy would be
             difficult to obtain or poses a high degree of risk to the subject, it may be deferred.

          -  Women of childbearing potential (WOCBP) must be willing to use 2 methods of birth
             control or be surgically sterile, or abstain from heterosexual activity for the course
             of the study, and for 6 months after the study is concluded. WOCBP are those who have
             not been surgically sterilized or have not been free from menses for > 1 year. The two
             birth control methods can be composed of: two barrier methods or a barrier method plus
             a hormonal method to prevent pregnancy. WOCBP subjects will also be instructed to tell
             their male partners to use a condom.

        Exclusion Criteria

          -  Subjects meeting any of the following exclusion criteria will not be able to
             participate in this study:

          -  Pregnant or lactating.

          -  Tumor in a location where enlargement could cause airway obstruction.

          -  Current use of systemic corticosteroids at doses ≥10mg prednisone daily or its
             equivalent; those receiving <10mg daily may be enrolled at discretion of the
             Investigator.

          -  Active infection with HIV, HTLV, HCV (can be pending at the time of cell procurement;
             only those samples confirming lack of active infection will be used to generate
             transduced cells) defined as not being well controlled on therapy. Subjects are
             required to have negative HIV antibody, negative HTLV1 and 2 antibody, and negative
             HCV antibody or viral load.

          -  Active infection with HBV. Subjects are required to have a negative Hepatitis B
             surface Antigen. In addition, subjects must either have core antibody negative HBV
             (results can be pending at the time of cell procurement) OR if a subject is Hepatitis
             B core antibody positive they must have their Hepatitis B viral load checked. These
             subjects will be excluded if their viral load is positive at baseline. Subjects who
             are core antibody positive and viral load negative at baseline will be considered
             eligible.

          -  Has a known additional malignancy that is active and/or progressive requiring
             treatment; exceptions include basal cell or squamous cell skin cancer, in situ
             cervical or bladder cancer, or other cancer for which the subject has been
             disease-free for at least three years.

          -  A history of intolerance to fludarabine. Subjects with an intolerance to bendamustine
             may be allowed to enroll at the discretion of the clinical investigator if he/she
             thinks that the subject is a candidate for lymphodepletion with cyclophosphamide and
             fludarabine.

          -  Subject is not a good candidate for treatment with ATLCAR.CD30.CCR4 with and without
             ATLCAR.CD30 per Investigator's discretion.

        Eligibility criteria to be met prior to procurement

        Evidence of adequate organ function as defined by:

        The following is required prior to procurement:

          -  Hgb ≥ 8.0g/dL (transfusion independent for 2 weeks prior to enrollment)

          -  Bilirubin ≤1.5 times the upper limit of normal (ULN). Subjects with Gilbert's syndrome
             may be enrolled despite a total bilirubin level >1.5 mg/dL if their conjugated
             bilirubin is <1.5× ULN

          -  AST ≤ 3 times ULN

          -  Serum creatinine ≤1.5 times ULN.

          -  Creatinine Clearance (CrCl) >60mL/min per Cockcroft and Gault

          -  Pulse oximetry of >90% on room air

          -  Imaging results from within 120 days prior to procurement to assess presence of active
             disease (no tumor imaging is required prior to procurement for participants with
             active cutaneous lymphoma).

          -  Negative serum pregnancy test within 72 hours prior to procurement or documentation
             that the subject is post-menopausal. Post-menopausal status must be confirmed with
             documentation of absence of menses for > 1 year, or documentation of surgical
             menopause involving bilateral oophorectomy.

          -  Subject has no clinical indication of rapidly progressing disease in opinion of
             treating physician.

          -  Subject has adequate cardiac function, defined as:

               -  No ECG evidence of acute ischemia

               -  No ECG evidence of active, clinically significant conduction system abnormalities

               -  Prior to study entry, any ECG abnormality at screening not felt to put the
                  subject at risk has to be documented by the Investigator as not medically
                  significant

               -  No uncontrolled angina or severe ventricular arrhythmias

               -  No clinically significant pericardial disease

               -  No history of myocardial infarction within the last 6 months prior to infusion

               -  No Class 3 or higher New York Heart Association Congestive Heart Failure

        Eligibility criteria to be met prior to lymphodepletion

          -  Presence of active disease. Imaging results from within 7 days prior to
             lymphodepletion to confirm presence of active disease. Subjects who have received
             bridging chemotherapy must have imaging performed at least 3 weeks after most recent
             therapy (imaging does not need to be repeated if it is within 7 days prior to
             lymphodepletion).

        Evidence of adequate organ function as defined by:

        The following are required prior to lymphodepletion:

          -  Adequate bone marrow function (ANC>1000 cells/mm3 and platelets >75,000/mm3). Subjects
             cannot have received platelet transfusion within 7 days of lymphodepletion.

          -  Bilirubin ≤1.5 times the upper limit of normal (ULN). Subjects with Gilbert's syndrome
             may be enrolled despite a total bilirubin level >1.5 mg/dL if their conjugated
             bilirubin is <1.5× ULN)

          -  AST ≤ 3 times ULN

          -  Serum creatinine ≤1.5 times ULN.

          -  Creatinine Clearance (CrCl) >60mL/min per Cockcroft and Gault

          -  Pulse oximetry of > 90% on room air

          -  Negative serum pregnancy test within 72 hours prior to lymphodepletion or
             documentation that the subject is post-menopausal. Post-menopausal status must be
             confirmed with documentation of absence of menses for > 1 year or documentation of
             surgical menopause involving bilateral oophorectomy.

          -  Subjects must have autologous transduced activated T-cells that meet the Certificate
             of Analysis (CofA) acceptance criteria.

          -  Has not received any investigational agents or received any tumor vaccines within the
             previous six weeks prior to lymphodepletion.

          -  Has not received anti-CD30 antibody-based therapy within the previous 4 weeks prior to
             lymphodepletion.

          -  Has not received chemotherapy or radiation therapy within the previous 3 weeks prior
             to lymphodepletion.

        Subjects cannot be on strong inhibitors of CYP1A2 (e.g., fluvoxamine, ciprofloxacin) as
        these may increase plasma concentrations of bendamustine, and decrease plasma
        concentrations of its metabolites. See http://medicine.iupui.edu/clinpharm/ddis/ for an
        updated list of strong inhibitors of CYP1A2. (This applies to subjects who receive
        bendamustine for lymphodepletion (required) up through 72 hours after the last dose of
        bendamustine).

          -  Subjects who are HBV core antibody positive and HBV viral load negative prior to
             lymphodepletion must have initiated anti-HBV prophylaxis prior to lymphodepletion.

          -  Subject has no clinical indication of rapidly progressing disease in the opinion of
             the treating physician.

          -  Subject is a good candidate for treatment with ATLCAR.CD30.CCR4 with and without
             ATLCAR.CD30 per the investigator's discretion.

        Eligibility criteria to be met prior to cell infusion after lymphodepletion

          -  No evidence of uncontrolled infection or sepsis.

        Evidence of adequate organ function as defined by:

          1. Bilirubin ≤2 times the upper limit of normal (ULN) unless attributed to Gilbert's
             syndrome

          2. AST ≤3 times ULN

          3. ALT ≤3 times ULN

          4. Creatinine Clearance (CrCl) >60mL/min per Cockcroft and Gault

          5. Pulse oximetry of >90% on room air

               -  Subject has no clinical indication of rapidly progressing disease in the opinion
                  of the treating physician.

               -  Subject is a good candidate for treatment with ATLCAR.CD30.CCR4 with and without
                  ATLCAR.CD30 per the investigator's discretion.